



Living Cell Technologies Limited

ACN: 104 028 042

ASX: LCT

OTCQB: LVCLY

ASX ANNOUNCEMENT

2022 AGM Update – Withdrawal of Resolutions

Sydney, Australia & Auckland, New Zealand – 1 November 2022 – In accordance with ASX Listing Rule 3.17A.2, Living Cell Technologies Limited (ASX: LCT; OTCQB: LVCLY) (**Company**) advises that Resolutions 7-12 in the Company's Notice of 2022 Annual General Meeting dated 30 September 2022 (**Notice**), being resolutions requisitioned by a group of shareholders under s249D of the *Corporations Act 2001* (Cth), have been withdrawn by those shareholders due to the recent resignations of Professor Bernard Tuch, Mr Robert Willcocks and Dr Andrew Kelly as directors of the Company and the appointment of Mr David Hainsworth and Mr Bradley Dilkes to the Board.

Accordingly, the following resolutions will not be considered at the Company's 2022 Annual General Meeting (**AGM**):

1. Resolution 2 – Re-election of Mr Robert Willcocks as a Director
2. Resolution 3 – Re-election of Dr Andrew Kelly as a Director
3. Resolution 7 - Appointment of Director – Mr Richard David Hainsworth
4. Resolution 8 - Appointment of Director – Mr Bradley John Dilkes
5. Resolution 9 - Removal of Director – Professor Bernard Tuch
6. Resolution 10 - Removal of Director – Dr Andrew Kelly
7. Resolution 11 - Removal of Director – Mr Robert Moyse Willcocks
8. Resolution 12 - Removal of Interim Appointed Directors

All other item of business included in the Notice will be put to shareholders at the AGM.

While the withdrawal of resolutions 2, 3 and 7-12 does not affect the validity of the Notice, the Company will provide an Addendum to the Notice to supplement the Notice and an updated Proxy Form in due course. The Addendum to the Notice will provide further information on the validity of proxy votes already cast by shareholders and on the resolutions to be considered at the AGM, including the additional resolutions for the re-election of Mr Richard David Hainsworth and Mr Bradley John Dilkes as directors of the Company.

Refer to the Company's announcement on 14 September 2022 entitled "*Receipt of Section 249D Notice*" for further information on the requisitioned resolutions and the Company's announcement on 31 October 2022 entitled "*Board Changes*" for further information on the recent changes to the Board.

Authorised for release by the Board of Living Cell Technologies Limited.

– Ends –

For further information: www.lctglobal.com

At the Company: Bradley Dilkes Director Mobile: +61 422 180 317 brad@alignmentcapital.com.au	For media queries: Anthony Fensom Republic PR Mobile: +61 407 112 623 anthony@republicpr.com.au
---	---

About NTCELL

NTCELL is an alginate coated capsule containing clusters of neonatal porcine choroid plexus cells that are sourced from a unique herd of designated pathogen-free pigs bred from stock originally discovered in the remote sub-Antarctic Auckland Islands. Choroid plexus cells are naturally occurring 'support' cells for the brain and secrete cerebrospinal fluid (CSF), which contains a range of factors that support nerve cell functions and protective enzymes that are crucial for nerve growth and healthy functioning. In NTCELL, the porcine choroid plexus cells are coated with alginate to protect them from attack by the immune system. Therefore, no immunosuppressive regimen needs to be administered to recipients.

About Living Cell Technologies

Living Cell Technologies Limited (ASX:LCT) is an Australasian biotechnology company that is focused on discovering and developing novel treatments for debilitating conditions such as diabetes and Parkinson's disease.

LCT is listed on the Australian (ASX:LCT) and US (OTCQB:LVCLY) stock exchanges. The Company is incorporated in Australia, with its operations based in Australia and New Zealand.

For more information, visit www.lctglobal.com or follow @lctglobal on Twitter, Facebook or LinkedIn.

Forward-looking statements

This document may contain certain forward-looking statements, relating to LCT's business, which can be identified by the use of forward-looking terminology such as "promising," "probable", "plans," "anticipated," "will," "project," "believe," "forecast," "expected," "estimated," "targeting," "aiming," "set to," "potential," "seeking to," "goal," "could provide," "intends," "is being developed," "could be," "on track," or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other health authorities' requirements regarding any one or more product candidates, nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialisation of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialise, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. LCT is providing this information and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.